CClinicalTrials.gg
CompletedNCT02201537Imag-NCTUpdated Nov 20, 2025

Kidney Disease and Ultrasound Imaging

An interventional study of renal echography in Recipient of Kidney Transplant, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Screening

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Mar 2013, registered Jul 2014).
Phase
Not applicable
Study type
Interventional
Enrollment
141
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The hypothesis of our study is that a correlation exists between the couple ultrasound elastography- renal perfusion estimated with contrast-enhanced ultrasound and the degree of fibrosis estimated in a semi-quantitative way in 4 stages (0; 25 %; 25-50 %; > 50 %), as elastography alone did not allow to differentiate moderated fibrosis at 3 months in our feasibility study.

Read the detailed description

Kidney transplant patients are exposed to long-term immunosuppressive therapy, and have an increased risk of infections and cancer, while a lack of treatment increases the risk of rejection. The development of imaging techniques to characterize the status of the graft remains a challenge in transplantation. Ideally, they should identify complications (acute rejection, chronic allograft nephropathy, nephrotoxicity ...) without the need for invasive procedures and thus lead to better customization of immunosuppressive therapy.

The post-transplant follow-up is based on the monitoring of graft function. Impaired function suggests the possibility of a complication, but requires confirmation by an invasive procedure such as renal biopsy. In addition, the diagnosis remains complex at a relatively advanced stage of the process due to damage to the graft parenchyma. To anticipate the altered function and detect subclinical lesions, screening biopsies have been used to diagnose chronic rejection. By definition, screening for subclinical lesions can not be based on any biological parameter; the diagnosis of subclinical complications thus requires performing multiple systematic biopsies, which are scheduled at 3 months and 1 year.

Doppler ultrasound is an imaging method of choice for the study of renal transplant, but it cannot diagnose the NCT due to the absence of specific findings. The lack of early diagnostic test for NCT is a major obstacle to the development and evaluation of new therapeutic options to prevent, slow or stabilize renal fibrosis. It is therefore necessary to develop a non-invasive imaging technique for the early diagnosis of NCT.

Ultrasound elastography is a technique that allows tissue stiffness measurements and provides a parametric picture.

The main objective of our study is to evaluate the performances of elastography and measurement of renal perfusion (area under the ROC curve) to diagnose the NCT and determine for each both measures a threshold to maximize the sensitivity. These performances will be evaluated at 3 months and 12 months. The results can also be compared to other imaging modalities such as functional MRI, and to clinical events (obstruction, infection…).

Functional ultrasound imaging should identify diagnostic and prognostic criteria of NCT, and enable the development of less invasive therapeutic protocols to evaluate new therapeutic approaches

02

Conditions studied

  • Recipient of Kidney Transplant

Keywords

  • Ultrasound functional imaging
  • Chronic kidney Nephropathy
03

In context

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥ 18 years;
  • Patient with informed consent;
  • Recipient of a living donor graft or cadaveric donor patient;
  • No contraindication for biopsy of the graft;
  • No contraindication to the injection of SonoVue ®:

    • hypersensitivity to sulfur hexafluoride
    • acute coronary syndrome, unstable ischemic heart disease (myocardial infarction phase formation or evolution, typical resting angina in the previous 7 days, significant worsening of cardiac symptoms in the previous 7 days, recent intervention on the coronary arteries or another factor suggesting clinical instability (eg, recent deterioration of ECG changes in clinical or laboratory parameters), acute heart failure, stage III or IV heart failure, severe arrhythmias.
    • right-left shunt, severe pulmonary hypertension (PAP> 90 mmHg), uncontrolled systemic hypertension, respiratory distress syndrome
  • Affiliated to a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study;
  • Inability / refusal to give informed consent;
  • contraindication for biopsy testing graft;
  • Presence of a contraindication to the injection of SonoVue ®.
  • Presence of a peripheral venous access in a non-restricted already infused patient, not pickable under ultrasound
  • Breastfeeding, pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Other
    Imag-NCT

    The ultrasound functional imaging will be performed at J15 (before the patient is discharged from service Transplantation) and at 3 and 12 months after the transplant. The functional imaging examinations will be held as follows: * 1st stage - the conventional Doppler ultrasound: * 2nd stage - the elastography:. * Step 3 - CEUS: It is performed on an ultrasound machine with a specific module with the same probes as conventional ultrasound. It requires the injection of 1.5 ml of SonoVue ®, a contrast ultrasound. Renal biopsy will be performed after the functional ultrasound at 3 and 12 months.

    Device: renal echography

Interventions

  • Devicerenal echography

    Renal biopsy will be performed at 3 and 12 months. The functional imaging examinations will be held as follows: Step 1: the conventional Doppler ultrasound Step 2: ultrasound elastography Step 3: CEUS

06

What researchers measure

Primary outcomes

  1. renal Elastography

    The assessment of renal function is performed by the serum creatinine and calculation of glomerular filtration rate estimated by the formula Modified Diet in Renal Disease (MDRD) 4-parameter at 3 and 12 months post-transplantation. In addition, a measure of glomerular filtration rate using the technique to iohexol is performed routinely at 12 months post-transplant as part of routine monitoring of transplant patient. The ultrasound functional imaging will be performed at 15 days, 3 and 12 months after transplantation. The functional imaging examinations will be held as follows: Step 1: the conventional Doppler ultrasound 2nd step: the ultrasound elastography Step 3 : CEUS

    Time frame: 3 months

  2. Renal Elastography and contrast-enhanced US

    The assessment of renal function is performed by the serum creatinine and calculation of glomerular filtration rate estimated by the formula Modified Diet in Renal Disease (MDRD) 4-parameter at 3 and 12 months post-transplantation. In addition, a measure of glomerular filtration rate using the technique to iohexol is performed routinely at 12 months post-transplant as part of routine monitoring of transplant patient. The ultrasound functional imaging will be performed at 15 days, 3 and 12 months after transplantation. The functional imaging examinations will be held as follows: Step 1: the conventional Doppler ultrasound 2nd step: the ultrasound elastography Step 3 : CEUS

    Time frame: 12 months

Secondary outcomes

  1. renal Elastography

    Correlation between elastography and renal function with degree of fibrosis and renal function will be calculate using Pearson coefficient of correlation

    Time frame: 3 months

  2. Correlation between renal elastography and perfusion and degree of fibrosis and renal function

    Correlation between elastography and renal function with degree of fibrosis and renal function will be calculate using Pearson coefficient of correlation

    Time frame: 12 months

  3. renal Elastography in patients with chronic kidney disease

    this two measures will be express in evolution percentage at J15 and 3 months. The evolution percentage will be compared with imaging of patient with chronic kidney disease to determine if elastography and renal perfusion can predict chronic kidney disease at one year.

    Time frame: 12 months

07

Study locations

1 site
  • NECKER Hospital
    Paris, 75015, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02201537
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Fondation de l'Avenir, Bracco Imaging S.p.A., URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Jul 28, 2014
Start date
Mar 19, 2013
Primary completion
Mar 19, 2016
Completion
Mar 19, 2016
Last update
Nov 20, 2025

Study contacts

Jean-Michel CORREAS, PUPH
principal investigator · Necker Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion